Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03280563
Title A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche

Her2-receptor negative breast cancer


Atezolizumab + Ipatasertib

Atezolizumab + Bevacizumab + Exemestane

Atezolizumab + Cobimetinib

Atezolizumab + Bevacizumab + Fulvestrant

Atezolizumab + Bevacizumab + Tamoxifen

Atezolizumab + Fulvestrant + Ipatasertib


Atezolizumab + Fulvestrant

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.